The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

Figures & data

Table 1. Patient and treatment characteristics

	Entire (n = 69)	Imatinib pre-transplant	Imatinib post-transplant	Imatinib pre/post-transplant		P value
		(n = 24)	(n = 9)	Both (n = 11)	Neither (n = 25)
Gender (male/female)	45/24	16/8	5/4	7/4	17/8	0.484
Age (median, range)	29.5, 12–61	36, 26–54	21, 13–27	31, 22–61	21, 12–44	0.105
Diseases status at the time of transplants
CR1	36 (52.2%)	13	5	7	11	0.537
None CR1	33 (47.8%)	11	4	4	14
With myeloid lineage
Yes	22 (31.9%)	7	3	3	9	0.957
No	47 (68.1%)	17	6	8	16
Donor type
Related	35 (50.7%)	14	6	4	11	0.271
Unrelated	34 (49.3%)	10	3	7	14
HLA matching
Matched	43 (62.3%)	15	7	7	14	0.260
Mismatched	26 (37.7%)	9	2	4	11
Conditioning regimen
Standard	28 (40.6%)	14	5	4	5	0.152
Intensified	41 (59.4%)	10	4	7	20
GVHD prophylaxis
CsA+MTX	31 (44.9%)	10	5	6	10	0.549
CsA+MTX+ATG	26 (37.7%)	7	2	5	12
CsA+MTX+ATG+MMF	11 (15.9%)	6	2	0	3
CsA alone	1 (1.5%)	1	0	0	0
Prophylactic DLI
Yes	34 (49.3%)	14	4	8	8	0.197
No	35 (50.7%)	10	5	3	17

Note: CR1, the first complete remission; DLI, donor lymphocyte infusion.

Table 2. GVHD in the entire cohort

	Entire (n = 69)	Imatinib pre-transplant	Imatinib post-transplant	Imatinib pre/post-transplant		P value
		(n = 24)	(n = 9)	Yes (n = 11)	No (n = 25)
aGVHD
0–I	31 (44.9%)	11	4	4	12	0.943
II–IV	38 (55.1%)	13	5	7	13
cGVHD
None	36 (52.2%)	8	4	6	18	0.699
Limit	20 (29.0%)	13	2	3	2
Extensive	13 (18.8%)	3	3	2	5

Table 3. GVHD in 35 patients without prophylactic DLI

	Entire (n = 35)	Imatinib pre-transplant		P value	Imatinib post-transplant		P value
		Yes (n = 13)	No (n = 22)		Yes (n = 10)	No (n = 25)
aGVHD
0–I	13 (37.1%)	4	9	0.554	3	10	0.586
II–IV	22 (62.9%)	9	13		7	15
cGVHD
None	18 (51.4%)	6	12	0.970	6	12	0.826
Limit	9 (25.7%)	5	4		1	8
Extensive	8 (22.9%)	2	6		3	5

Figure 1. Lymphocyte subsets dynamic in peripheral blood after imatinib therapy in the patients underwent allo-HSCT.

Table 4. Univariate and multivariate analyses of risk factors

Risk factor	OS		DFS		Relapse
	Univariate	Multivariate	Univariate	Multivariate	Univariate	Multivariate
Age, <30 years vs. ≥30 years	NS	NS	NS	NS	NS	NS
The status at transplants, CR vs. nCR	P = 0.027	P = 0.035	P = 0.034	P = 0.047	P = 0.015	P = 0.029
With myeloid lineage, yes vs. no	NS	NS	NS	NS	NS	NS
Imatinib therapy, pre-HSCT vs. post-HSCT vs. both vs. neither	NS	NS	NS	NS	NS	NS
HLA typing, matched vs mismatched	NS	NS	NS	NS	NS	NS
Donor, related vs. unrelated	NS	NS	NS	NS	NS	NS
Conditioning, standard vs intensified	NS	NS	NS	NS	NS	NS
Acute GVHD, grades 0–I vs. II–IV	NS	NS	NS	NS	NS	NS
Chronic GVHD, yes vs. no	NS	NS	NS	NS	NS	NS
DLI, yes vs. no	NS	NS	NS	NS	NS	NS

Note: OS, overall survival; DFS, disease-free survival; NS, not significant; CR, complete remission; nCR, complete remission; HLA.

Figure 2. Relapse in patients received imatinib therapy or not post-transplant.